The agreement which is expected to close in the fourth quarter of 2023, or early 2024 depending on regulatory and shareholder approvals. Credit: Gajus/Shutterstock

US based medical device company, Spinal Stabilization Technologies is scheduled to take part in a business combination agreement with publicly traded special purpose acquisition company, BlueRiver Acquisition Corp.

Spinal Stabilization Technologies develops and markets lumbar implants for nucleus pulposus replacements and tackles various types of lower back pain. The company’s lead product, PerQdisc, which has not yet received FDA approval mimics the function of the nucleus pulposus to provide a motion-preserving surgical solution.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The agreement which is expected to close in the fourth quarter of 2023, or early 2024 depending on regulatory and shareholder approvals, will see the companies operate as Spinal Stabilization Technologies and list on an approved stock exchange.

Following the completion of the agreement, the combined companies would have an estimated value of $302 million. Any proceeds earned from the transaction will be put towards commercial expansion and fund an FDA pivotal trial which is set to begin in Q2 2024.

In November 2022, Spinal announced the start of their LOPAIN2 clinical trial of the PerQdisc nucleus replacement device which was studied in 72 patients with degenerative disc disease.

See Also:

In May 2021 the company also earned the CE Mark and the FDA’s breakthrough designation classification for its PerQdisc replacement system which at the time was the only available commercial lumbar nucleus replacement system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, the augmented discectomy market, valued at $4.8 billion and the degenerative disc disease market, valued at $4.6 billion are two opportunities they plan to break into with their PerQdisc system.